PE-firm Ampersand Capital Partners invests in GeneWerk
September 23, 2020
Ampersand Capital Partners has acquired a majority stake in Heidelberg-based gene and cell therapy testing laboratory GeneWerk GmbH, which was founded in 2014. Annette Deichmann, Co-Founder and Co-CEO at GeneWerk said that with the PE-firm as GeneWerk’s partner, the company is planning to strengthen and expand its position in the US and Europe. Financials of the deal remain undisclosed.
ⓘ This story was originally featured in our daily M&A Insights newsletter.